Article

Mortality and Comorbidities in MS

How do they compare with the non-MS population?


 

References

Rates of mortality and several comorbidities are higher in an MS versus non-MS cohort, according to a study of 15, 864 patients with MS and 78,420 people without MS. Researchers found that in the MS cohort compared with the non-MS cohort:

• All-causes mortality was 2.9 times higher.

• Relative risks of mortality were: infectious disease (6.2), diseases of the nervous system (5.8), respiratory system (5.0), circulatory system (2.1), and suicide (2.6).

• Relative risks of comorbidities were: sepsis (5.7), ischemic stroke (3.8), attempted suicide (2.4), and ulcerative colitis (2.0).

• The rate of cancers was higher: lymphoproliferative disorders (2.2) and melanoma (1.7).

Citation: Capkur G, Dahlke F, Lahoz R, et al. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US department of defense administrative claims database. [Published online ahead of print August 18, 2015]. Mul Scler Rel Dis. doi: http://dx.doi.org/10.1016/j.msard.2015.08.005.

Comment: Multiple sclerosis (MS) is not a benign disease; people with MS die at a rate higher than those without MS. This study reinforces the importance of early effective treatment to reduce disease burden and treat symptomatic problems in people who have MS. It is also just as important to identify and treat other significant comorbidities in those we treat for MS.—Mark Gudesblatt, MD, Medical Director of the Comprehensive MS Care Center at South Shore Neurologic Associates in Islip, NY

Recommended Reading

Discussing Treatment With Patients With Progressive MS
ICYMI Multiple Sclerosis
The Gut Microbiome May Aid the Treatment and Prevention of MS
ICYMI Multiple Sclerosis
Telephone Interventions for MS Patients
ICYMI Multiple Sclerosis
Alcohol and Smoking in MS
ICYMI Multiple Sclerosis
Lipoprotein Levels in BBB Injury
ICYMI Multiple Sclerosis
Patient Characteristics as Prognosticators
ICYMI Multiple Sclerosis
Tissue-Loss Markers
ICYMI Multiple Sclerosis
Researchers Seek Drugs to Promote Remyelination in Progressive MS
ICYMI Multiple Sclerosis
Are Effective Therapies for Progressive MS on the Horizon?
ICYMI Multiple Sclerosis
PML Observed in Three Patients With MS Treated With Fingolimod
ICYMI Multiple Sclerosis